<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790723</url>
  </required_header>
  <id_info>
    <org_study_id>15-007542</org_study_id>
    <nct_id>NCT02790723</nct_id>
  </id_info>
  <brief_title>Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA</brief_title>
  <acronym>AAVIL-1Ra</acronym>
  <official_title>A Phase I Study Evaluating the Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the safety of three different doses of sc-rAAV2.5IL-1Ra&#xD;
      delivered by intra-articular injection into one knee joint of patients with moderate OA of&#xD;
      the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing severe adverse events.</measure>
    <time_frame>53 weeks</time_frame>
    <description>Assess the local and systemic safety of three different doses of sc-rAAV2.5IL-1Ra delivered by intra-articular injection into one knee joint of patients with moderate OA of the knee.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Low Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sc-rAAV2.5IL-1Ra</intervention_name>
    <description>Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.</description>
    <arm_group_label>High Dose Group</arm_group_label>
    <arm_group_label>Low Dose Group</arm_group_label>
    <arm_group_label>Medium Dose Group</arm_group_label>
    <other_name>AAVIL-1Ra</other_name>
    <other_name>IL-1Ra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Gender: both males and females&#xD;
&#xD;
          -  Target disease: Moderate OA of the knee&#xD;
&#xD;
          -  Persistent symptoms, despite standard NSAID&#xD;
&#xD;
          -  Absence of clinically significant abnormal values for the following:&#xD;
&#xD;
          -  Complete blood count&#xD;
&#xD;
          -  Prothrombin Time, Activated partial thromboplastin time&#xD;
&#xD;
          -  Blood chemistry (Glucose, Na, K, Cl, CO2, BUN, creatinine, Ca, PO4, magnesium, uric&#xD;
             acid)&#xD;
&#xD;
          -  Liver function tests (amylase, total bilirubin, alkaline phosphate, GGT, AST, ALT,&#xD;
             total protein, albumin)&#xD;
&#xD;
          -  Able and willing to return to the Mayo Clinic for follow-up visits, as required by&#xD;
             this study&#xD;
&#xD;
          -  Able undergo MRI of the knee&#xD;
&#xD;
          -  Subjects should be able to give appropriate consent.&#xD;
&#xD;
          -  Potential subjects should have failed a three-month trial of a minimum of two&#xD;
             conservative therapies before being considered for this trial. These conservative&#xD;
             therapies include: activity modification, weight loss, physical therapy, and&#xD;
             anti-inflammatory or injection therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant, or currently breast-feeding&#xD;
&#xD;
          -  Ongoing infectious disease including HIV, HTLV, hepatitis, syphilis or tuberculosis&#xD;
             positive&#xD;
&#xD;
          -  Individuals who have OA as part of another syndrome (e.g. Ehler's Danlos, Stickler&#xD;
             syndrome, etc.)&#xD;
&#xD;
          -  Systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis,&#xD;
             hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with&#xD;
             juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic&#xD;
             arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and&#xD;
             synovial chondromatosis.&#xD;
&#xD;
          -  Clinically significant cardiovascular, renal, hepatic, endocrine disease, diabetes,&#xD;
             cancer, autoimmune diseases; a serious infection or major operation within 30 days of&#xD;
             enrollment; a history of untreated psychiatric disease or recent history of alcoholism&#xD;
             or drug addiction.&#xD;
&#xD;
          -  Currently taking immunosuppressant medications&#xD;
&#xD;
          -  Anticipated major surgery during the study period.&#xD;
&#xD;
          -  Individuals involved in another interventional protocol, or have been treated under&#xD;
             one within the last 3 months.&#xD;
&#xD;
          -  Intra-articular therapy in the index knee within the previous 3 months.&#xD;
&#xD;
          -  Surgery to the target knee within 6 months prior to screening.&#xD;
&#xD;
          -  Surgery to other weight bearing joints if it will interfere with knee assessments&#xD;
&#xD;
          -  Prior articular transplant procedures&#xD;
&#xD;
          -  Orthopedic hardware or implantable devices anywhere in the body, other than dental&#xD;
&#xD;
          -  Prior reconstruction surgery to the target knee within 12 months&#xD;
&#xD;
          -  X-ray findings of acute fractures&#xD;
&#xD;
          -  Known severe loss of bone density, and/or severe bone or joint deformity in the target&#xD;
             knee.&#xD;
&#xD;
          -  Significant target knee infection or overlying skin disorder/infection within the&#xD;
             previous 6 months prior to study enrollment&#xD;
&#xD;
          -  Require cane or other assistive device for walking&#xD;
&#xD;
          -  Symptomatic OA of the hips, spine or ankle if it would interfere with the evaluation&#xD;
             of the target knee,&#xD;
&#xD;
          -  History of documented nerve damage in the affected limb, or vascular insufficiency,&#xD;
&#xD;
          -  Condition requiring use of systemic steroids,&#xD;
&#xD;
          -  Coagulation disorder.&#xD;
&#xD;
          -  Patients with unstable knees&#xD;
&#xD;
          -  Temperature above 99.5o F.&#xD;
&#xD;
          -  Identification as a member of a vulnerable population.&#xD;
&#xD;
          -  BMI greater than 40.&#xD;
&#xD;
          -  History of allergy to local anesthetics&#xD;
&#xD;
          -  Currently taking anti-rheumatic disease medication (including methotrexate or other&#xD;
             antimetabolites) within the 3 months prior to entry in the study.&#xD;
&#xD;
          -  Any illness or condition which, in the investigators' judgement will interfere with&#xD;
             the patient's ability to comply with the protocol, compromise patient safety, or&#xD;
             interfere with the interpretation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher H. Evans, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Christopher H. Evans, Ph.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

